NCT07769255 Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
| NCT ID | NCT07769255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beni-Suef University |
| Condition | Chronic Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 146 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 146 participants in total. It began in 2026-09-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Early chronic migraine (\<6 months of ≥15 headache days/month), per ICHD-3 criteria. * No preventive migraine therapy in the prior 8 weeks. Exclusion Criteria: * Presence of cardiopulmonary, psychiatric, or neurological comorbidities. * Current use of sedatives, opioids, or CGRP-targeting therapies. * Pregnancy or breastfeeding.
Contact & Investigator
Hatem ElMoutaz Mahmoud, M.D
STUDY CHAIR
Professor of Anesthesiology, Surgical Intensive Care and Pain Management,Faculty of Medicine
Frequently Asked Questions
Who can join the NCT07769255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Chronic Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07769255 currently recruiting?
Yes, NCT07769255 is actively recruiting participants. Contact the research team at Ibthal21@gmail.com for enrollment information.
Where is the NCT07769255 trial being conducted?
This trial is being conducted at Banī Suwayf, Egypt.
Who is sponsoring the NCT07769255 clinical trial?
NCT07769255 is sponsored by Beni-Suef University. The principal investigator is Hatem ElMoutaz Mahmoud, M.D at Professor of Anesthesiology, Surgical Intensive Care and Pain Management,Faculty of Medicine. The trial plans to enroll 146 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.